GERMANTOWN, Md.–(BUSINESS WIRE)– Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system.

Click here to read the official press release in full.

By |2018-06-21T14:59:24+00:00April 2nd, 2018|CGM, Senseonics|0 Comments

About the Author: